Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Gilead Sciences logo
Gilead SciencesGILD
-$67M+36.2%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$6.28M+65.8%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$663K+297%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.9M-39.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.67M-3.1%

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s change in AP?
Artiva Biotherapeutics, Inc. (ARTV) reported change in AP of $1.81M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s change in AP changed year-over-year?
Artiva Biotherapeutics, Inc.'s change in AP increased by 4319.5% year-over-year, from $41K to $1.81M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.